S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
NYSE:DGX

Quest Diagnostics (DGX) Stock Price, News & Analysis

$124.68
-0.21 (-0.17%)
(As of 03/1/2024 ET)
Today's Range
$123.66
$124.99
50-Day Range
$123.78
$142.11
52-Week Range
$119.59
$148.62
Volume
1.03 million shs
Average Volume
1.03 million shs
Market Capitalization
$13.80 billion
P/E Ratio
16.65
Dividend Yield
2.28%
Price Target
$145.92

Quest Diagnostics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
17.0% Upside
$145.92 Price Target
Short Interest
Healthy
2.71% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.72mentions of Quest Diagnostics in the last 14 days
Based on 30 Articles This Week
Insider Trading
Selling Shares
$1.91 M Sold Last Quarter
Proj. Earnings Growth
7.31%
From $8.75 to $9.39 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.99 out of 5 stars

Medical Sector

3rd out of 947 stocks

Medical Laboratories Industry

1st out of 20 stocks


DGX stock logo

About Quest Diagnostics Stock (NYSE:DGX)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

DGX Stock Price History

DGX Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Living Our Purpose - Ivelisse Lugo
Birmingham-based Pack Health inks national grocery deal
Quest Descends on Release of Test Launch
See More Headlines
Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 1/31 Dividend
1/16/2024
Dividend Payable
1/31/2024
Last Earnings
2/01/2024
Today
3/03/2024
Ex-Dividend for 4/22 Dividend
4/05/2024
Dividend Payable
4/22/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Health Care Services
CUSIP
74834L10
Employees
48,000
Year Founded
1967

Price Target and Rating

Average Stock Price Target
$145.92
High Stock Price Target
$165.00
Low Stock Price Target
$130.00
Potential Upside/Downside
+17.0%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
12 Analysts

Profitability

Net Income
$854 million
Pretax Margin
12.21%

Debt

Sales & Book Value

Annual Sales
$9.25 billion
Cash Flow
$12.75 per share
Book Value
$57.29 per share

Miscellaneous

Free Float
108,825,000
Market Cap
$13.80 billion
Optionable
Optionable
Beta
0.90

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report














DGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Quest Diagnostics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DGX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DGX, but not buy additional shares or sell existing shares.
View DGX analyst ratings
or view top-rated stocks.

What is Quest Diagnostics' stock price target for 2024?

12 analysts have issued twelve-month price targets for Quest Diagnostics' shares. Their DGX share price targets range from $130.00 to $165.00. On average, they anticipate the company's stock price to reach $145.92 in the next year. This suggests a possible upside of 17.0% from the stock's current price.
View analysts price targets for DGX
or view top-rated stocks among Wall Street analysts.

How have DGX shares performed in 2024?

Quest Diagnostics' stock was trading at $137.88 at the start of the year. Since then, DGX shares have decreased by 9.6% and is now trading at $124.68.
View the best growth stocks for 2024 here
.

Are investors shorting Quest Diagnostics?

Quest Diagnostics saw a drop in short interest in the month of February. As of February 15th, there was short interest totaling 2,970,000 shares, a drop of 13.7% from the January 31st total of 3,440,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is currently 2.9 days. Approximately 2.7% of the shares of the stock are sold short.
View Quest Diagnostics' Short Interest
.

When is Quest Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our DGX earnings forecast
.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) posted its quarterly earnings data on Thursday, February, 1st. The medical research company reported $2.15 EPS for the quarter, beating the consensus estimate of $2.11 by $0.04. The medical research company earned $2.29 billion during the quarter, compared to analysts' expectations of $2.25 billion. Quest Diagnostics had a trailing twelve-month return on equity of 15.79% and a net margin of 9.23%. The business's quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.98 earnings per share.
Read the conference call transcript
.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics announced a quarterly dividend on Thursday, February 1st. Investors of record on Monday, April 8th will be paid a dividend of $0.75 per share on Monday, April 22nd. This represents a $3.00 dividend on an annualized basis and a yield of 2.41%. The ex-dividend date is Friday, April 5th. This is a positive change from the stock's previous quarterly dividend of $0.71.
Read our dividend analysis for DGX
.

Is Quest Diagnostics a good dividend stock?

Quest Diagnostics (NYSE:DGX) pays an annual dividend of $2.84 per share and currently has a dividend yield of 2.28%. The company has been increasing its dividend for 13 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 37.92%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DGX will have a dividend payout ratio of 30.24% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DGX.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics announced that its board has authorized a share buyback plan on Thursday, February 2nd 2023, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 6% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's board of directors believes its shares are undervalued.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its FY24 earnings guidance on Thursday, February, 1st. The company provided earnings per share guidance of $8.60-8.90 for the period, compared to the consensus EPS estimate of $8.98. The company issued revenue guidance of $9.35-9.45 billion, compared to the consensus revenue estimate of $9.38 billion.

What is Steve Rusckowski's approval rating as Quest Diagnostics' CEO?

1,053 employees have rated Quest Diagnostics Chief Executive Officer Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), Abbott Laboratories (ABT), NVIDIA (NVDA), Intel (INTC) and Cisco Systems (CSCO).

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (12.08%), Victory Capital Management Inc. (3.09%), Price T Rowe Associates Inc. MD (2.32%), Dimensional Fund Advisors LP (1.75%), Wells Fargo & Company MN (1.37%) and Northern Trust Corp (0.99%). Insiders that own company stock include Catherine T Doherty, Gail R Wilensky, Michael E Prevoznik, Michael J Deppe, Stephen H Rusckowski, Stephen H Rusckowski, Timothy M Ring and Vicky B Gregg.
View institutional ownership trends
.

How do I buy shares of Quest Diagnostics?

Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Quest Diagnostics have any subsidiaries?
The following companies are subsidiares of Quest Diagnostics: AmeriPath, AmeriPath Cincinnati Inc. (OH), AmeriPath Cleveland Inc. (OH), AmeriPath Consolidated Labs Inc. (FL), AmeriPath Florida LLC (DE), AmeriPath Hospital Services Florida LLC (DE), AmeriPath Inc. (DE), AmeriPath Indianapolis PC (IN), AmeriPath Kentucky Inc. (KY), AmeriPath Lubbock 5.01(A) Corporation (TX), AmeriPath New York LLC (DE), AmeriPath Texas Inc. (DE), AmeriPath Tucson Inc. (AZ), American Medical Laboratories, American Medical Laboratories Incorporated (DE), Associated Clinical Laboratories L.P. (PA), Associated Clinical Laboratories of Pennsylvania L.L.C. (PA), Athena Diagnostics, Athena Diagnostics Inc. (DE), Blueprint Genetics, Blueprint Genetics FZ-LLC (UAE), Blueprint Genetics Inc. (DE), Blueprint Genetics Oy (Finland), California Laboratory Associates, Cape Cod Healthcare - Business, Celera, ClearPoint Diagnostic, Clearpoint Diagnostic Laboratories LLC (TX), Cleveland HeartLab, Cleveland HeartLab Inc. (DE), Clinical Laboratory Partners, Colorado Pathology Consultants P.C. (CO), ConVerge Diagnostic Services, Consolidated DermPath Inc. (DE), DFW 5.01(a) Corporation (TX), DGXWMT JV LLC (DE), Dermatopathology of Wisconsin S.C. (WI), Diagnostic Laboratory of Oklahoma LLC (OK), Diagnostic Pathology Services Inc. (OK), Diagnostic Reference Services Inc. (MD), ExamOne Canada Inc. (New Brunswick), ExamOne LLC (DE), ExamOne World Wide Inc. (PA), ExamOne World Wide of NJ Inc. (NJ), Focus Diagnostics, HemoCue, Hoffman M.D. Associated Pathologists Chartered (NV), Institute for Dermatopathology Inc. (PA), Isabella Street Urban Renewal LLC (NJ), Kailash B. Sharma M.D. Inc. (GA), Kilpatrick Pathology P.A. (NC), LabOne, LabOne LLC (MO), LabOne of Ohio Inc. (DE), Laboratorio de Analisis Biomedicos S.A. (Mexico), Lancet Labs, MACL, Med Fusion LLC (TX), Med fusion, MedPlus, Mid America Clinical Laboratories LLC (IN), Nomad Massachusetts Inc. (MA), Nuclear Medicine and Pathology Associates (GA), Ocmulgee Medical Pathology Association Inc. (GA), Pathology Building Partnership (MD) (gen. ptnrshp.), PeaceHealth Laboratories, PhenoPath Laboratories, PhenoPath Laboratories PLLC (WA), Q Squared Solutions Holdings LLC (DE), Q Squared Solutions Holdings Limited (UK), Quest Diagnostics (Shanghai) Co. Ltd. (China), Quest Diagnostics Brasil Holdings Ltd. (UK), Quest Diagnostics Clinical Laboratories, Quest Diagnostics Clinical Laboratories Inc. (DE), Quest Diagnostics Domestic Holder LLC (DE), Quest Diagnostics HTAS India Private Limited (India), Quest Diagnostics Health & Wellness LLC (DE), Quest Diagnostics Holdings Incorporated (DE), Quest Diagnostics Holdings Ltd. (UK), Quest Diagnostics Incorporated (MD), Quest Diagnostics Incorporated (NV), Quest Diagnostics India Private Limited (India), Quest Diagnostics Infectious Disease Inc. (DE), Quest Diagnostics International Holdings Limited (UK), Quest Diagnostics International LLC (DE), Quest Diagnostics Investments LLC (DE), Quest Diagnostics Ireland Limited (Ireland), Quest Diagnostics LLC (CT), Quest Diagnostics LLC (IL), Quest Diagnostics LLC (MA), Quest Diagnostics Massachusetts LLC (MA), Quest Diagnostics Mexico Holding Company Trust (Mexico), Quest Diagnostics Mexico S de RL de CV (Mexico), Quest Diagnostics Nichols Institute (CA), Quest Diagnostics Nichols Institute Inc. (VA), Quest Diagnostics Receivables Inc. (DE), Quest Diagnostics Subsidiary Holdings Ltd. (UK), Quest Diagnostics TB LLC (DE), Quest Diagnostics Terracotta LLC (DE), Quest Diagnostics Venture LLC (PA), Quest Diagnostics Ventures LLC (DE), Quest Diagnostics do Brasil Ltda. (Brazil), Quest Diagnostics of Pennsylvania Inc. (DE), Quest Diagnostics of Puerto Rico Inc. (PR), Quest HealthConnect LLC (CA), ReproSource, Reprosource Fertility Diagnostics Inc. (MA), Solstas Lab Partners, Sonora Quest Laboratories LLC (AZ), Specialty Laboratories Inc. (CA), Summit Health, UMass Memorial Medical Center - Anatomic Pathology Outreach Laboratory Business, Unilab Corporation, and Unilab Corporation (DE).
Read More
This page (NYSE:DGX) was last updated on 3/3/2024 by MarketBeat.com Staff